STOCK TITAN

Theratechnologies to Announce First Quarter 2024 Financial Results and Provide Business Update

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
earnings
Rhea-AI Summary
Theratechnologies Inc. will report financial results and provide a business update for its first quarter on April 10, 2024. The call will be hosted by CEO Paul Lévesque and other key members of the management team.
Positive
  • None.
Negative
  • None.

MONTREAL, April 03, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced the Company will report financial results and provide a business update for its first quarter ended February 29, 2024, on Wednesday, April 10 at 8:30 a.m. ET.

The call will be hosted by Paul Lévesque, President and Chief Executive Officer. Mr. Lévesque will be joined by other members of the management team, including Philippe Dubuc, Senior Vice President and Chief Financial Officer, Christian Marsolais, Ph.D., Senior Vice President and Chief Medical Officer and John Leasure, Global Commercial Officer who will be available to answer questions from participants following prepared remarks.

Participants are encouraged to join the call at least ten minutes in advance to secure access. Conference call dial-in and replay information can be found below.

CONFERENCE CALL INFORMATION
Conference Call DateApril 10, 2024
Conference Call Time8:30 a.m. ET
Webcast linkhttps://edge.media-server.com/mmc/p/pozhpvit
Dial in1-888-513-4119 (toll free) or 1-412-902-6615 (international)
Access Code4991919
CONFERENCE CALL REPLAY
Toll Free1-877-344-7529 (US) / 1-855-669-9658 (Canada)
International Toll1-412-317-0088
Replay Access Code3783831
Replay End DateApril 17, 2024
To access the replay using an international dial-in number, please select this link:
https://services.choruscall.com/ccforms/replay.html

An archived webcast will also be available on the Company’s Investor Relations website under ‘Past Events’.

About Theratechnologies

Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Further information about Theratechnologies is available on the Company's website at www.theratech.com, on SEDAR+ at www.sedarplus.ca and on EDGAR at www.sec.gov. Follow Theratechnologies on Linkedin and X (formerly Twitter). 

Contacts:

Investor inquiries:
Philippe Dubuc
Senior Vice President and Chief Financial Officer
pdubuc@theratech.com
438-315-6608

Media inquiries:
Julie Schneiderman
Senior Director, Communications & Corporate Affairs
communications@theratech.com
1-514-336-7800

 


Theratechnologies Inc. will report financial results for its first quarter on April 10, 2024.

The call will be hosted by Paul Lévesque, President and CEO of Theratechnologies Inc., along with other key members of the management team.

Participants can find the webcast link for the conference call at https://edge.media-server.com/mmc/p/pozhpvit.

Participants can access the conference call replay by dialing 1-877-344-7529 (US) / 1-855-669-9658 (Canada) for toll-free access, or 1-412-317-0088 for international access. The replay access code is 3783831.
Theratechnologies Inc.

NASDAQ:THTX

THTX Rankings

THTX Latest News

THTX Stock Data

Pharmaceutical Preparation Manufacturing
Manufacturing
Link
Health Technology, Pharmaceuticals: Major, Manufacturing, Pharmaceutical Preparation Manufacturing
Canada
Montreal

About THTX

theratechnologies inc., a biopharmaceutical company, markets prescription products in the united states, europe, and canada. it offers egrifta and egrifta sv, for the reduction of excess abdominal fat in human immunodeficiency virus (hiv)-infected patients with lipodystrophy; and trogarzo, an injection refers to ibalizumab for the treatment of multidrug resistant hiv-1 infected patients. the company's pipeline products include f8 formulation that could be used for the treatment of hiv-associated lipodystrophy; th-1902 for the treatment of triple negative breast cancer; and th-1904 for the treatment of ovarian cancer. the company was founded in 1993 and is headquartered in montreal, canada.